Promega
Promega Corporation, a leading biotechnology company headquartered in the United States, has been at the forefront of life sciences since its founding in 1978. With a strong presence in North America, Europe, and Asia, Promega focuses on providing innovative solutions for molecular biology, genomics, and protein analysis. The company is renowned for its core products, including luciferase-based assays, DNA and RNA purification kits, and cell culture reagents, which are distinguished by their reliability and ease of use. Promega's commitment to quality and innovation has solidified its position as a trusted partner in research and development across various industries, including pharmaceuticals, diagnostics, and academic research. Notable achievements include numerous patents and a robust portfolio that supports advancements in scientific discovery, making Promega a pivotal player in the global biotechnology landscape.
DitchCarbon Score
How does Promega's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Promega's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Promega's reported carbon emissions
In 2024, Promega Corporation reported total carbon emissions of approximately 31,616,000 kg CO2e, a decrease from about 37,073,000 kg CO2e in 2023. The emissions breakdown for 2024 includes 10,765,000 kg CO2e from Scope 1, 6,214,000 kg CO2e from Scope 2, and 14,637,000 kg CO2e from Scope 3. This trend indicates a commitment to reducing their carbon footprint, particularly in Scope 1 and Scope 2 emissions. Promega has set near-term climate targets and is committed to sustainability initiatives, although specific reduction targets have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is based in the United States. Their emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. Overall, Promega's ongoing efforts reflect a proactive approach to addressing climate change and reducing carbon emissions across all scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 8,158,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,281,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 12,571,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Promega is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
